Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKLR | P30613 | 3/20 | 1.00 |
| ▸ | GALNT2 | Q10471 | 2/20 | 1.00 |
| ▸ | GALNT1 | Q10472 | 1/20 | 1.00 |
| ▸ | GALNT3 | Q14435 | 1/20 | 1.00 |
| ▸ | GALNT10 | Q86SR1 | 1/20 | 1.00 |
| ▸ | GALNT13 | Q8IUC8 | 1/20 | 1.00 |
| ▸ | GALNT6 | Q8NCL4 | 1/20 | 1.00 |
| ▸ | GALNT14 | Q96FL9 | 1/20 | 1.00 |
| ▸ | ACE | P12821 | 1/20 | 0.60 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.58 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.58 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.58 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.58 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.58 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.58 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.58 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.58 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.58 |
| ▸ | MET | P08581 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29370098 | 1.00 | PKLR (1.00) | PKLRGALNT2GALNT1GALNT3GALNT10 | |
| SCHEMBL26768213 | 0.89 | PKLR (0.79) | PKLRGALNT2GALNT1GALNT3GALNT10 | |
| SCHEMBL7987277 | 0.81 | ESR2 (0.70) | PKLRGALNT2GALNT1GALNT3GALNT10 | |
| SCHEMBL29466713 | 0.81 | PKLR (0.68) | PKLRGALNT2GALNT1GALNT3GALNT10 | |
| SCHEMBL29827270 | 0.81 | PKLR (0.68) | PKLRGALNT2GALNT1GALNT3GALNT10 | |
| SCHEMBL2357304 | 0.81 | PKLR (0.68) | PKLRGALNT2GALNT1GALNT3GALNT10 | |
| SCHEMBL17949557 | 0.80 | PKLR (0.66) | PKLRGALNT2GALNT1GALNT3GALNT10 | |
| SCHEMBL7984298 | 0.79 | ESR2 (0.75) | PKLRGALNT2GALNT1GALNT3GALNT10 | |
| SCHEMBL3874869 | 0.77 | ATP1A1 (0.74) | PKLRGALNT2GALNT1GALNT3GALNT10 | |
| SCHEMBL9748319 | 0.76 | ATP1A1 (0.61) | PKLRGALNT2GALNT1GALNT3GALNT10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114760996-A | Direct AMPK activator compounds in combination with indirect AMPK activator compounds, compositions, methods, and uses thereof | 雀巢产品有限公司 | 2022-07-15 | — | — | CN | claimed |
| WO-2021105074-A1 | DIRECT AMPK ACTIVATOR COMPOUNDS COMBINED WITH INDIRECT AMPK ACTIVATOR COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF | Société des Produits Nestlé S.A. (CH) | 2021-06-03 | — | — | WO | claimed |
| CN-122075479-A | Application of urolithin D in preparation of drugs for inhibiting and/or preventing and/or relieving and/or treating acute kidney injury | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4555997-A1 | WATER-SOLUBLE COMPOSITION COMPRISING UROLITHIN | Science4Beauty Sp. z o.o. (PL) | 2025-05-21 | — | — | EP | disclosed |
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2023-11-21 | — | — | US | disclosed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| EP-2866804-B1 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS OR PRECURSORS THEREOF | AMAZENTIS SA (CH) | 2023-09-13 | — | — | EP | disclosed |
| EP-4233858-A1 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS OR PRECURSORS THEREOF | Amazentis SA (CH) | 2023-08-30 | — | — | EP | disclosed |
| US-20230263769-A1 | APPLICATIONS OF ELLAGIC ACID AND METABOLIC DERIVATIVES THEREOF IN PREPARATION OF IMMUNOMODULATORY MEDICINES | SHAANXI NORMAL UNIVERSITY (CN) | 2023-08-24 | — | — | US | disclosed |
| US-20230263769-A1 | APPLICATIONS OF ELLAGIC ACID AND METABOLIC DERIVATIVES THEREOF IN PREPARATION OF IMMUNOMODULATORY MEDICINES | SHAANXI NORMAL UNIVERSITY (CN) | 2023-08-24 | — | — | US | disclosed |
| US-20160000753-A1 | Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2016-01-07 | — | — | US | disclosed |
| US-20150336981-A1 | MODIFIED POLYPHENOLS AND MODIFIED POLYPHENOL COMPOSITIONS | CELLAROUGE PTY LTD (AU) | 2015-11-26 | — | — | US | disclosed |
| US-20150336981-A1 | MODIFIED POLYPHENOLS AND MODIFIED POLYPHENOL COMPOSITIONS | CELLAROUGE PTY LTD (AU) | 2015-11-26 | — | — | US | disclosed |
| EP-2862568-A1 | Compositions comprising urolithins and uses thereof for the stimulation of insulin secretion | Centre National de la Recherche Scientifique (CNRS) (FR) | 2015-04-22 | — | — | EP | disclosed |
| US-20140018415-A1 | Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof | AMAZENTIS SA (CH) | 2014-01-16 | — | — | US | disclosed |
| US-20140018415-A1 | Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof | AMAZENTIS SA (CH) | 2014-01-16 | — | — | US | disclosed |
| US-6194439-B1 | ANTICANCER AGENT | PFIZER INC. | 2001-02-27 | — | — | US | disclosed |
| EP-0586608-A1 | TRICYCLIC POLYHYDROXYLIC TYROSINE KINASE INHIBITORS | PFIZER INC. (US) | 1994-03-16 | — | — | EP | disclosed |
| WO-1992021660-A1 | TRICYCLIC POLYHYDROXYLIC TYROSINE KINASE INHIBITORS | PFIZER, INC. (US) | 1992-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000753-A1 | Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof | ATG7, BECN1, ATG4A | PKLR 2385/4885GALNT2 138/4885GALNT1 148/4885 |
| US-20150336981-A1 | MODIFIED POLYPHENOLS AND MODIFIED POLYPHENOL COMPOSITIONS | PGC, COMT, EGLN2 | PKLR 1239/4885GALNT2 150/4885GALNT1 115/4885 |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | SI, FABP2, CEL | PKLR 1716/4885GALNT2 104/4885GALNT1 140/4885 |
| US-20140018415-A1 | Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof | ATG7, BECN1, ATG4A | PKLR 2385/4885GALNT2 138/4885GALNT1 148/4885 |
| US-20230263769-A1 | APPLICATIONS OF ELLAGIC ACID AND METABOLIC DERIVATIVES THEREOF IN PREPARATION OF IMMUNOMODULATORY MEDICINES | OGT, TXN, UGGT1 | PKLR 3762/4885GALNT2 42/4885GALNT1 47/4885 |
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | PKLR 1783/4885GALNT2 445/4885GALNT1 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.